申请人:Cadila Pharmaceuticals Ltd.
公开号:US20200095195A1
公开(公告)日:2020-03-26
The present invention relates to novel intermediate(s), which are useful for the preparation of Rivastigmine compound of formula (I) and its pharmaceutically acceptable salts. The present invention further relates to the processes for the preparation of such novel intermediate(s) and preparation of Rivastigmine using such novel intermediate(s).
本发明涉及新型中间体,该中间体对于制备化合物Rivastigmine的公式(I)及其药用可接受的盐是有用的。本发明还涉及制备这种新型中间体的方法以及使用这种新型中间体制备Rivastigmine的方法。